OTC · Biotechnology

America Great Health (AAGH) Stock

$0.00 OTC: AAGH Healthcare

Operating as a U.S.-based biotechnology company, America Great Health (AAGH) focuses on two primary areas: the research and development of protein and peptide small molecular drugs, and the manufacturing and sale of a diverse portfolio including AI cloud computing-driven diagnostic and medical devices, cell therapies, regenerative medicine, and supplements. The company, which originated as Crown Marketing, adopted the name America Great Health in March 2017.

Valuation

MetricValue
Price$0.00
Market Cap$2.12M
P/E Ratio1.00
P/B Ratio-0.46
P/S Ratio5.38
EPS (TTM)$0.00
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE16.67%
ROA-103.67%
ROCE16.70%
Gross Margin70.28%
Operating Margin-440.74%
Net Margin164.42%
Debt/Equity-0.50
Current Ratio0.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0$-5.0M$0$-1.0M$0
Net Profit$0$-5.0M$-1.0M$-1.0M$-1.0M
EPS$0.00$0.00$0.00$0.00$0.00
Op Margin-124.5%-4523.8%-241.1%-265.6%-97.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$0$0$0$0
Total Liabilities$1.0M$4.0M$5.0M$6.0M$6.0M
Cash$0$0$0$0$0
Borrowings$1.0M$1.0M$2.0M$2.0M$3.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$-1.0M$-1.0M$0
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$0$0$0$0$0
Free Cash Flow$0$-1.0M$-1.0M$-1.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA3.68
FCF Yield-19.29%
Quick Ratio0.02
Interest Coverage0.81
Return 1Y-66.67%
Return 3Y-97.50%
Return 5Y—

Ownership

Insiders Held9.16%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXSAyala Pharmaceuticals, Inc. $0.60 +0.00% -0.08 $25.71M 0.00%
AGNPFGrey Matters Health Inc. $0.25 -17.12% -0.43 $869804 0.00%
AGTXAgentix Corp. $0.02 +0.00% -2.00 $801339 0.00%
APLIFAppili Therapeutics Inc $0.01 +0.00% -0.44 $1.46M 0.00%
HESGHealth Sciences Group, Inc. $0.00 — 0.00 $1.87M 0.00%

About America Great Health

Operating as a U.S.-based biotechnology company, America Great Health (AAGH) focuses on two primary areas: the research and development of protein and peptide small molecular drugs, and the manufacturing and sale of a diverse portfolio including AI cloud computing-driven diagnostic and medical devices, cell therapies, regenerative medicine, and supplements. The company, which originated as Crown Marketing, adopted the name America Great Health in March 2017. Established in 2013, AAGH's headquarters are located in Alhambra, California.

America Great Health (AAGH) stock trades at $0.00 with a market capitalization of $2.12M. The stock is valued at a price-to-earnings (P/E) ratio of 1.00, a negative price-to-book of -0.46, reflecting negative shareholders' equity, price-to-sales of 5.38.

On profitability, America Great Health generates a return on equity (ROE) of 16.67% (not meaningful, as shareholders' equity is negative), return on capital employed of 16.70%, an operating margin of -440.74%, a net profit margin of 164.42%.

Official website: www.aaghus.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.